BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35820543)

  • 1. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
    Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
    Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
    Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
    Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFNγ induces Bcl3 expression by JAK1/STAT1/p65 signaling, resulting in increased IL-8 expression in ovarian cancer cells.
    Gaire B; Padmanabhan S; Zou Y; Uddin MM; Reddy SU; Vancurova I
    FEBS Open Bio; 2023 Aug; 13(8):1495-1506. PubMed ID: 37151134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
    Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
    Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
    Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
    Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of PD-L1 Transcriptional Regulation in Ovarian Cancer Cells by Chromatin Immunoprecipitation.
    Zou Y; Padmanabhan S; Vancurova I
    Methods Mol Biol; 2020; 2108():229-239. PubMed ID: 31939185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.
    Padmanabhan S; Zou Y; Vancurova I
    Methods Mol Biol; 2020; 2108():211-220. PubMed ID: 31939183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells.
    Padmanabhan S; Zou Y; Vancurova I
    Methods Mol Biol; 2020; 2108():221-228. PubMed ID: 31939184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8
    Wang Y; Shen Y; Liang J; Wang S; Huang Y; Zhu Q; Zhang X; Yu K; Tong G; Yang C; Li Y; Wang J; Zhao Y
    J Neuroinflammation; 2024 May; 21(1):119. PubMed ID: 38715061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
    Wu Y; Zhou L; Zou Y; Zhang Y; Zhang M; Xu L; Zheng L; He W; Yu K; Li T; Zhang X; Chen Z; Zhang R; Zhou P; Zhang N; Zheng L; Kang T
    Nat Cancer; 2023 Mar; 4(3):382-400. PubMed ID: 36894639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma.
    Kong SK; Kim BS; Lim H; Kim HJ; Kim YS
    Lab Invest; 2022 Apr; 102(4):352-362. PubMed ID: 34789838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
    Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I
    J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
    Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
    Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFNγ induces JAK1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration.
    Padmanabhan S; Gaire B; Zou Y; Uddin MM; DeLeon D; Vancurova I
    Int J Biochem Cell Biol; 2021 Dec; 141():106093. PubMed ID: 34626802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Delivery of an Adenoviral Vector Carrying the
    Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
    Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.
    Hagiwara Y; Sato H; Permata TBM; Niimi A; Yamauchi M; Oike T; Nakano T; Shibata A
    Hum Immunol; 2018 Aug; 79(8):627-631. PubMed ID: 29859207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
    Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
    Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
    Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
    Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.